<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175902</url>
  </required_header>
  <id_info>
    <org_study_id>cosopt-IOP/OPP</org_study_id>
    <nct_id>NCT01175902</nct_id>
  </id_info>
  <brief_title>Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma</brief_title>
  <official_title>To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared
      to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular
      perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG)

      Clinical hypotheses. Primary hypothesis

        -  Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction.

      Secondary hypothesis

        -  Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cosopt (dorzolamide/timolol fixed combination) has well known effect for IOP reduction in
      POAG and OHT.3-5 However, there is no study about the effect and safety of Cosopt in NTG,
      Cosopt is not used the first line drug in the management of NTG.

      In Korea, the prevalence of NTG is higher than western countries, the majority (about 80-90%)
      of open angle glaucoma patients have an IOP of 21 mmHg or less, so the study of NTG is
      important and searching of effective drug for the treatment of NTG is necessary.

      In this study, we would prove the non-inferiority of Cosopt compared to Xalatan,6 which is
      used as a first line drug in the management of NTG, in the aspects of IOP and OPP including
      diastolic OPP (DOPP).

      A prospective, interventional, randomized, crossover, single masked, single center study.
      Forty-four NTG patients were randomly allocated to one of two groups. Patients in group A
      were treated with Cosopt, lubricant, and Xalatan for 4 weeks each, whereas patients in group
      B were treated with Xalatan, lubricant, and Cosopt for 4 weeks each.

      Recruit NTG patients, who are not treated with the glaucoma medication recent 2 months. If
      treated, after washout period of 4 weeks, the patients can be included in the study. Baseline
      IOP, systolic and diastolic BP will be measured. (Day 1) After 4 weeks of treatment of Cosopt
      or Xalatan, all participants will be checked diurnal IOP, systolic and diastolic BP. IOP was
      measured by Goldmann applanation tonometry (mean of three consecutive readings) with the
      patient in a sitting position at the slit lamp. Every IOP will be measured by one masked
      glaucoma specialist who is unaware of the treatment assignments. After the IOP measurements,
      after a 5-minite rest, pulse rate and BP (systolic and diastolic) of radial artery were
      measured in the sitting position using a standard automated blood pressure cuff. During the
      period, all measuring instruments keep to be calibrated by the manufacturer's instruction.

      - OPP was calculated according to the following formula: OPP=(1/3 systolic BP + 2/3 diastolic
      BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP. During the 4 weeks washout period,
      subjects will use lubricants.(Week 8) In this crossover study, with the other eye drops, the
      same measurement will be performed. (Week 12)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP), Period 1</measure>
    <time_frame>4 weeks</time_frame>
    <description>IOP (mean IOP) after 4 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP), Period 2</measure>
    <time_frame>12 weeks</time_frame>
    <description>IOP (mean IOP) after treaemt from week 8 to week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure (BP), Period 1</measure>
    <time_frame>4 weeks</time_frame>
    <description>systolic and diastolic BP at 4 weeks after use of eyedrops</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure (BP), Period 2</measure>
    <time_frame>12 weeks</time_frame>
    <description>systolic and diastolic BP measured after treaemt from week 8 to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Perfusion Pressure (OPP), Period 1</measure>
    <time_frame>4 weeks</time_frame>
    <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPP, Period 2</measure>
    <time_frame>12 weeks</time_frame>
    <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP
OPP after treaemt from week 8 to week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide/timolol</intervention_name>
    <description>dorzolamide/timolol fixed combination eyedrop, 2 times a day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Cosopt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost</intervention_name>
    <description>compare with dorzolamide/timolol fixed combination eyedrop one time a day</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The identification of NTG was based on reproducible glaucomatous visual field defects,
        corresponding to typical ONH changes.

        Unilateral or bilateral visual field loss (description as below) as determined by at least
        two consecutive automated static threshold perimetry tests.

        One eye is randomly selected in the cases where both eyes are treated.

        Inclusion criteria:

          1. age ranging from 45 to 75 years

          2. best-corrected visual acuity no worse than 20/30 Snellen equivalent

          3. optic nerve head cupping (i.e., a vertical cup-to-disc ratio of more than 0.6) and/or
             notching of neuroretinal rim, and/or retinal nerve fiber defects characteristic of
             glaucoma

          4. visual field loss (i.e., a localized defect with at least three adjacent nonedge
             points depressed &gt;5 dB from the normal value, and a nucleus of at least one point
             depressed 10 dB from the normal value)

          5. repeated measurements of untreated IOP, which documented values less than 22 mmHg

          6. central corneal thickness ranging from 540 to 560 microns

          7. open-angle confirmed by gonioscopy

        Exclusion criteria:

          1. active or chronic systemic diseases and/or concomitant assumption of any medication
             known to affect IOP, BP and/or HR

          2. corneal abnormalities preventing reliable applanation tonometry

          3. severe ocular trauma, ocular inflammation or infection, intraocular surgery or argon
             laser treatment or laser trabeculoplasty

          4. myopic or other fundus changes preventing reliable optic disc evaluation,

          5. visual field defects caused by nonglaucomatous disease

          6. history of allergy to the ingredients of Cosopt or Xalatan eye drops
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chan Kee Park, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <results_first_submitted>November 26, 2014</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Chan Kee Park</investigator_full_name>
    <investigator_title>Seoul St. Mary's Hospital</investigator_title>
  </responsible_party>
  <keyword>Normal tension glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seoul St. Mary's Hospital From April, 5th, 2011 to October, 16th, 2014</recruitment_details>
      <pre_assignment_details>44 enrolled, 44 completed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Latanoprost</title>
          <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
        <group group_id="P2">
          <title>Dorzolamide/Timolol</title>
          <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Latanoprost</title>
          <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
        <group group_id="B2">
          <title>Dorzolamide/Timolol</title>
          <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.72" spread="7.42"/>
                    <measurement group_id="B2" value="59.68" spread="7.12"/>
                    <measurement group_id="B3" value="60.20" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spherical equivalent</title>
          <description>Sperical equvalaent comes from refractive error of the patient and it is calcaulated as the algebraic sum of the value of the sphere and half the cylindrical value.</description>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.74" spread="1.95"/>
                    <measurement group_id="B2" value="-1.04" spread="2.71"/>
                    <measurement group_id="B3" value="-0.89" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central corneal thickness</title>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="542.73" spread="11.43"/>
                    <measurement group_id="B2" value="544.23" spread="17.33"/>
                    <measurement group_id="B3" value="543.48" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean deviation of visual field</title>
          <units>decibels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.00" spread="3.79"/>
                    <measurement group_id="B2" value="-2.92" spread="2.96"/>
                    <measurement group_id="B3" value="-3.46" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP), Period 1</title>
        <description>IOP (mean IOP) after 4 weeks of treatment</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 1</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 1</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP), Period 1</title>
          <description>IOP (mean IOP) after 4 weeks of treatment</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IOP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.72" spread="2.93"/>
                    <measurement group_id="O2" value="13.50" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.27" spread="2.37"/>
                    <measurement group_id="O2" value="13.36" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.54" spread="2.30"/>
                    <measurement group_id="O2" value="12.63" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" spread="2.50"/>
                    <measurement group_id="O2" value="13.77" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.36" spread="1.89"/>
                    <measurement group_id="O2" value="13.63" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between two arms were made for IOP, systolic BP, diastolic BP and OPP at each time period.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To prove the non-inferiority of Cosopt to Xalatan, the sample size calculation was based on the assumption that non-inferiority margin of trough IOP of 1.5mmHg. A sample size of n=21 patients per group, this study has 80% power (1-β=0.80) and α=0.05, crossover-designed analysis.
In this study, the upper limit of the 95% CI is expected above the maximal acceptable clinically significant difference of 1.5 mmHg of IOP.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>Comparison between two arms were made for IOP, systolic BP, diastolic BP and OPP at each time period.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Comparison between two arms were made for IOP, systolic BP, diastolic BP and OPP at each time period.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Comparison between two arms were made for IOP, systolic BP, diastolic BP and OPP at each time period.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP), Period 2</title>
        <description>IOP (mean IOP) after treaemt from week 8 to week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 2</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 2</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP), Period 2</title>
          <description>IOP (mean IOP) after treaemt from week 8 to week 12</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IOP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="3.02"/>
                    <measurement group_id="O2" value="12.36" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.81" spread="3.21"/>
                    <measurement group_id="O2" value="12.36" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.54" spread="3.05"/>
                    <measurement group_id="O2" value="12.72" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.81" spread="3.24"/>
                    <measurement group_id="O2" value="13.04" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IOP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.40" spread="2.36"/>
                    <measurement group_id="O2" value="13.13" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure (BP), Period 1</title>
        <description>systolic and diastolic BP at 4 weeks after use of eyedrops</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 1</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 1</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure (BP), Period 1</title>
          <description>systolic and diastolic BP at 4 weeks after use of eyedrops</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic BP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.82" spread="16.25"/>
                    <measurement group_id="O2" value="122.82" spread="17.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.68" spread="12.76"/>
                    <measurement group_id="O2" value="119.14" spread="18.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.45" spread="13.22"/>
                    <measurement group_id="O2" value="120.55" spread="17.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.09" spread="13.14"/>
                    <measurement group_id="O2" value="118.55" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.32" spread="14.09"/>
                    <measurement group_id="O2" value="119.45" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.77" spread="11.45"/>
                    <measurement group_id="O2" value="77.36" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.50" spread="11.13"/>
                    <measurement group_id="O2" value="73.81" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.22" spread="9.71"/>
                    <measurement group_id="O2" value="73.18" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.27" spread="10.35"/>
                    <measurement group_id="O2" value="72.81" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.95" spread="11.78"/>
                    <measurement group_id="O2" value="74.13" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure (BP), Period 2</title>
        <description>systolic and diastolic BP measured after treaemt from week 8 to week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 2</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 2</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure (BP), Period 2</title>
          <description>systolic and diastolic BP measured after treaemt from week 8 to week 12</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic BP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.14" spread="12.58"/>
                    <measurement group_id="O2" value="118.41" spread="15.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.59" spread="12.06"/>
                    <measurement group_id="O2" value="117.95" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.41" spread="11.89"/>
                    <measurement group_id="O2" value="119.05" spread="13.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.50" spread="12.78"/>
                    <measurement group_id="O2" value="118.45" spread="14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>systolic BP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.23" spread="14.88"/>
                    <measurement group_id="O2" value="119.82" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.45" spread="7.71"/>
                    <measurement group_id="O2" value="73.72" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.86" spread="8.40"/>
                    <measurement group_id="O2" value="72.50" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.54" spread="7.89"/>
                    <measurement group_id="O2" value="72.40" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.45" spread="7.50"/>
                    <measurement group_id="O2" value="71.36" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic BP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.81" spread="8.64"/>
                    <measurement group_id="O2" value="74.72" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Perfusion Pressure (OPP), Period 1</title>
        <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 1</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 1</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Perfusion Pressure (OPP), Period 1</title>
          <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.57" spread="8.34"/>
                    <measurement group_id="O2" value="49.12" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.65" spread="6.81"/>
                    <measurement group_id="O2" value="46.95" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.21" spread="6.64"/>
                    <measurement group_id="O2" value="48.17" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.81" spread="7.14"/>
                    <measurement group_id="O2" value="45.44" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.79" spread="7.34"/>
                    <measurement group_id="O2" value="46.73" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OPP, Period 2</title>
        <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP
OPP after treaemt from week 8 to week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Latanoprost, Period 2</title>
            <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
          <group group_id="O2">
            <title>Dorzolamide/Timolol, Period 2</title>
            <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
          </group>
        </group_list>
        <measure>
          <title>OPP, Period 2</title>
          <description>OPP was calculated according to the following formula:
OPP=(1/3 systolic BP + 2/3 diastolic BP) x 2/3 -IOP, diastolic OPP (DOPP)=diastolic BP-IOP
OPP after treaemt from week 8 to week 12</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPP at 8am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.36" spread="6.00"/>
                    <measurement group_id="O2" value="46.71" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 10am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.04" spread="5.98"/>
                    <measurement group_id="O2" value="46.07" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 12pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.47" spread="5.98"/>
                    <measurement group_id="O2" value="45.90" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 16pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.81" spread="6.21"/>
                    <measurement group_id="O2" value="44.99" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPP at 20pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.10" spread="6.70"/>
                    <measurement group_id="O2" value="46.70" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 12 weeks study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Latanoprost</title>
          <description>Patients on Latanoprost eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
        <group group_id="E2">
          <title>Dorzolamide/Timolol</title>
          <description>Patients on Dorzolamide/Timolol eyedrops
dorzolamide/timolol fixed combination: Cosopt eyedrop, 2 times a day
latanoprost: compare with Cosopt one time a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chan Kee Park</name_or_title>
      <organization>Seoul St. Mary's Hospital</organization>
      <phone>82222586208</phone>
      <email>ckpark@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

